ProCE Banner Series

2023 PCE Gastroenterology APP Bootcamp

Join us for this interactive GI Bootcamp to keep your gastroenterology practice up to date! Nationally renowned faculty will provide the latest insights into managing diseases of the GI tract including inflammatory bowel disease, the microbiome in C difficile, and much more. Educational programming is tailored to meet the clinical needs of NPs and PAs in gastroenterology, with practical perspectives and case study discussions. Live streamed for your convenience—so you can learn from the comfort of your home or office!

This activity is in partnership with the American Gastroenterological Association (AGA).

  | ANCC
Credits Available

Attendees can earn 4.0 CE/CME credits, including pharmacology credit for NPs.

Who Should Attend

NPs and PAs who practice in gastroenterology.

All Events

2023 PCE Gastroenterology APP Bootcamp

Past Events




10:00 AM - 4:10 PM Eastern Time (ET)



ProCE Banner Faculty
Jordan Axelrad, MD, MPH

Associate Professor
NYU Grossman School of Medicine
Clinical and Translational Research
Inflammatory Bowel Disease Center at NYU Langone Health
New York, New York

ProCE Banner Faculty
Andrea Banty, DNP, FNP

Nurse Practitioner
Cedars-Sinai IBD Center
Los Angeles, California

ProCE Banner Faculty
Brooks Cash, MD

Dan and Lilly Sterling Professor of Medicine
Department of Medicine
McGovern Medical School
Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston/Memorial Hermann Hospital
Houston, Texas

ProCE Banner Faculty
Tedra Gray, MS, ACNP-BC

Lead Management Advance Practice Provider
Sinai Chicago 
Chicago, Illinois

ProCE Banner Faculty
Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN

Advanced Practice Provider Leader, IBD APN, Ostomy Specialist
Department of Medicine, Section of Gastroenterology  
IBD Center
University of Chicago
Chicago, Illinois

ProCE Banner Faculty
Colleen Kelly, MD, FACG, AGAF

Associate Professor of Medicine
Division of Gastroenterology
Warren Alpert Medical School of Brown University
Providence, Rhode Island


Topics Include:

  • Constipation
  • Inflammatory Bowel Disease
  • Microbiome in C. difficile

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.


Target Audience
NPs and PAs who practice in gastroenterology. 

For the IBD topic:

Learning Objectives:
Upon completion of this activity, learners should be better able to: 

  • Employ a treat-to-target approach into the management of patients with inflammatory bowel disease (IBD)
  • Integrate clinical evidence, recent real-world data, current guidance, and patient preferences into individualized treatment plans for patients with IBD
  • Devise a plan for long-term management of IBD that includes addressing treatment-related adverse events

For the Microbiome topic:

Learning Objectives:
Upon completion of this activity, learners should be better able to:

  • Review the impact of gut dysbiosis on the development of recurrent Clostridium difficile infection (CDI)
  • Apply evidence-based treatment strategies for patients with CDI based on guideline recommendations
  • Detail the safety and efficacy for emerging standardized microbiota therapies for recurrent CDI

For the Constipation topic:

Learning Objectives:
Upon completion of this activity, learners should be better able to:

  • Implement guideline recommendations to establish a differential diagnosis of chronic constipation
  • Apply nonpharmacologic approaches for the management of CIC and IBS-C in patients
  • Formulate personalized approaches for use of novel therapies for CIC and IBS-C


Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

ANCC Credit Designation

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 4.0 contact hours, including 2.5 hours of pharmacology credit.
       - Constipation: 1.5 contact hours
       - IBD: 1.5 contact hours
       - Microbiome: 1.0 contact hour

AAPA Credit Designation

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
       - Constipation: 1.5 AAPA Categroy 1 CME Credits       
       - IBD: 1.5 AAPA Category 1 CME credits
       - Microbiome: 1.0 AAPA Category 1 CME credit 

IPCE Credit Designation


This activity was planned by and for the healthcare team, and learners will receive 4.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
       - Constipation: 1.5 IPCE credits        
       - IBD: 1.5 IPCE credits
       - Microbiome: 1.0 IPCE credit

Disclosure of Conflicts of Interest 

Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


Provided by Partners for Advancing Clinical Education (PACE)

In partnership with American Gastroenterological Association.

Supported by educational grants from AbbVie Inc.; Bristol Myers Squibb; Ferring Pharmaceuticals, Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.